Advanced Biosciences Laboratories, PATH Partner in Vaccine Production - - BioPharm International

ADVERTISEMENT

Advanced Biosciences Laboratories, PATH Partner in Vaccine Production


Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization, has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate. ABL will develop a scalable GMP production process to produce toxicology and Phase I clinical supply at its facility located in Rockville, Maryland.

The vaccine candidate is based on IpaB/IpaD fusion protein technology developed in the laboratory of Wendy Picking, associate professor in the Department of Microbiology and Molecular Genetics at Oklahoma State University. The IpaB and IpaD proteins are highly conserved within Shigella species and, therefore, are expected to stimulate broad protective immune responses against multiple serotypes, according to ABL.

Source: ABL

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines

Click here